Novel aminoglycoside antibiotic based on new understanding of ototoxicity. Leads show broad-spectrum antimicrobial activity and substantially less ototoxicity and nephrotoxicity in animals.
Novel broadly-protective influenza vaccine. Currently optimizing protein folding and developing a cold-chain independent production scheme. Plan ferret testing within a year.
sk09111 Novel target to treat heart failure through agonist activity. Proof-of-concept animal studies supported link between target signaling and cardiac function.
sk07081 Small molecule inducer of melanin production/tanning response as therapy for xeroderma pigmentosum (XP), vitiligo, erythropoietic protoporphyria (EPP).
Innovative platform to enhance Adeno-associated virus (AAV)-based gene therapy. Identified a host factor to improve AAV infection for all serotypes and cell types.
sk08095 Combination therapeutic monoclonal antibody plus engineered immune cells to treat acute gastrointestinal graft versus host disease (GVHD) (orphan disease).
sk08096 Small molecule inducer of beta cell regeneration for treatment of type 2 diabetes. Lead compound optimization on-going.
sk08091 Novel targets for induction of brown fat from white fat to treat obesity. Preparing high-throughput screening to identify small molecule inhibitors.
sk09105 Repurposed small molecule to prevent cancer emergence in patients with inherited BRCA-1 mutants (orphan disease). Establishing biomarkers and in consultation with FDA about trial endpoints. Good drug safety record, but never approved in USA.
sk10128 Topical formulation of a small molecule plant extract to prevent radiation dermatitis, salivary indications and possibly dry eyes during cancer treatment. Currently in preclinical testing.
Charge –Altering Releasable Transporters (CARTS): New materials enable a new platform technology for gene delivery, vaccinations, and cancer immunotherapy
sk08078 Diagnostic predictor for risk of Kawasaki Disease in children for use in combination with in silico tool. Validating biomarkers in patient samples.
sk09113 A minimally invasive diagnostic method to detect intestinal mucosal injury that precedes the onset of fulminant NEC. An ELISA based assay development is currently underway for selected biomarkers.
Inexpensive, point-of-care diagnostic to measure chemotherapy-induced hyperammonemia (“chemo brain”) and inborn errors of ammonia metabolism.